Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 29;9:966028. doi: 10.3389/fcvm.2022.966028

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 de Laat, Stragier, de Laat-Kremers, Ninivaggi, Mesotten, Thiessen, Van Pelt, Roest, Penders, Vanelderen, Huskens, De Jongh, Laenen, Fivez, ten Cate, Heylen, Heylen and Steensels.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The association of thrombin generation parameters and clinical symptoms after the second round of vaccination as reported by subjects vaccinated with ChAdOx1-S with and without prior COVID-19 infection. (A,B) The lag time did not differ significantly at the increasing levels of injection site symptoms (A) or systemic symptoms (B). The peak height differed significantly between subjects with increasing injection site symptoms (p < 0.038), although the study was underpowered to detect differences between specific groups in post hoc analysis (C). Increasing systemic symptoms did not result in differences in peak height (D). (E,F) The time-to-peak differed significantly between the categories of injection site symptoms (p = 0.029) (E), but not systemic symptoms (F). (G,H) The ETP was not significantly affected by the various levels of injection site symptoms (G) or systemic symptoms (H). (I) The velocity index was significantly increased in subjects with more injection site symptoms (p < 0.001) (I), but not systemic symptoms (J). Data are displayed as mean and standard deviation or as percentages in the case of categorical variables. Differences between the groups were analyzed by ANOVA or Kruskal-Wallis analysis, depending on the distribution of the data. A p-value below 0.05 was considered statistically significant and ^*** indicates a p-value below 0.001.